GE sells CodeLink microarray business to SurModics
SurModics, a provider of surface modification and drug delivery technologies to the healthcare industry, has acquired the CodeLink activated slide microarray business from GE Healthcare. Terms of the transaction were not disclosed.
The acquisition of the CodeLink activated slide business further demonstrates SurModics’ desire to build on its portfolio of in vitro technologies, according to Bruce Barclay, president and CEO of Eden Prairie, Minn.-based SurModics. “On the heels of our successful acquisition of BioFX Laboratories in August 2007, we continue to enhance the breadth of our in vitro technologies product portfolio.”
The company said that CodeLink activated slides use SurModics' PhotoLink technology to create a 3D matrix that allows the attachment of biomolecules (including DNA, RNA and proteins) to form microarrays. SurModics provides surface chemistry to the microarray field. SurModics continues to manufacture the products, which since 2000 have been marketed by Motorola, then Amersham and most recently by GE under the CodeLink brand.
The acquisition of the CodeLink activated slide business further demonstrates SurModics’ desire to build on its portfolio of in vitro technologies, according to Bruce Barclay, president and CEO of Eden Prairie, Minn.-based SurModics. “On the heels of our successful acquisition of BioFX Laboratories in August 2007, we continue to enhance the breadth of our in vitro technologies product portfolio.”
The company said that CodeLink activated slides use SurModics' PhotoLink technology to create a 3D matrix that allows the attachment of biomolecules (including DNA, RNA and proteins) to form microarrays. SurModics provides surface chemistry to the microarray field. SurModics continues to manufacture the products, which since 2000 have been marketed by Motorola, then Amersham and most recently by GE under the CodeLink brand.